On this page
Treatment of carcinoid tumor depends on the location, size, and spread of the tumor. Typically, surgery is the first step and aims to remove as much of the tumor as possible. If any tumor remains following surgery, or if the tumor has spread to distant parts of the body (metastasized), medications such as octreotide, everolimus, or other chemotherapy drugs may be used to treat this condition.
Last updated: 10/23/2014
- National Comprehensive Cancer Network. Neuroendocrine Tumors. NCCN Clinical Practice Guidelines in Oncology. 2014; http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed 11/22/2014.
- Tebbi CK. Carcinoid Tumor Treatment & Management. Medscape. 2014; http://emedicine.medscape.com/article/986050-treatment. Accessed 10/23/2014.
- ClinicalTrials.gov lists trials that are studying or have studied Carcinoid tumor. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
- The Research Portfolio Online Reporting Tool (RePORT) provides access to reports, data, and analyses of research activities at the National Institutes of Health (NIH), including information on NIH expenditures and the results of NIH-supported research. Although these projects may not conduct studies on humans, you may want to contact the investigators to learn more. To search for studies, enter the disease name in the "Text Search" box. Then click "Submit Query".
Medical ProductsThe medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.
(Novartis Pharmaceuticals Corporation)
The FDA has approved this product to be used in this manner.
|Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.|
|More Information about this product||
Drug Information Portal
Medline Plus Health Information